Humoral immune response to immunocomplexed HIV envelope glycoprotein 120

AIDS Research and Human Retroviruses

Volumn 12, Issue 10, 1996, Pages 901-909

  Denisova, Galina ^a   Stern, Baruch ^a   Raviv, Daphna ^a   Zwickel, Judith ^a   Smorodinsky, Nechama I ^a   Gershoni, Jonathan M ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; PROTEINASE; T LYMPHOCYTE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; STAPHYLOCOCCUS AUREUS; T LYMPHOCYTE; VIRUS ENVELOPE;

EID: 0029987644     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.901     Document Type: Article

References (54)

1. Shearer GM and Wigzell H: Vaccines and immunology. AIDS 1994;8:131-132.
2. Cease KB and Berzofsky JA: Toward a vaccine for AIDS: The emergence of immunobiology-based vaccine development. Annu Rev Immunol 1994;12:923-989.
3. Bolognesi DP: Human immunodeficiency virus vaccines. Adv Virus Res 1993;42:103-148.
4. Nara PL, Garrity RR, and Goudsmit J: Neutralization of HIV-1: A paradox of humoral proportions. FASEB J 1991;5:2437-2455.
5. Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, Jellis CL, Profy AT, Rusche JR, Bolognesi DP, Putney SD, and Matthews TJ: Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci USA 1989;86:6768-6772.
6. Hahn BH, Shaw BM, Taylor ME, Redfield RR, Markham PD, Salahuddin SZ, Wong-Staal F, Gallo RC, Parks ES, and Parks WP: Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science 1986;232:1548-1553.
7. Clerici M and Shearer GM: A TH1-TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107-111.
8. Allan H, Gersten MJ, Salk PL, and Salk J: Can AIDS be prevented by T-cell vaccination? Immunol Today 1993;14:200-202.
9. Mazanec MB, Nedrud JG, Kaetzel CS, and Lamm ME: A three-tiered view of the role of IgA in mucosal defense. Immunol Today 1993;14:430-434.
10. Lee T-H, Chou M-J, Huang J-H, Yu X-F, Allen J, McLane MF, Marlink R, Essex M, Redfield RR, Burke DS, Hsieh C-C, and Saah A: Association between antibody to envelope glycoprotein gp120 and the outcome of human immunodeficiency virus infection. Vaccines 1988;88:373-377.
11. Corny MK, Xu JY, Karwowska S, Buchbinder A, and Zolla-Pazner S: Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol 1993; 130:635-643.
12. IIIB gp120 that neutralize infectivity, block binding to CD4, and react with diverse isolates. AIDS Res Hum Retroviruses 1992; 8:1875-1885.
13. Gorny MK, Xu JY, Gianakakos V, Karwowska S, Williams C, Sheppard HW, Hanson CV, and Zolla-Pazner S: Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci USA 1991; 88:3238-3242.
14. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PWHI, Sawyer LSW, Hendry RM, Dunlop N, Nara PL, Lamacchia M, Garratty E, Stiehm ER, Bryson YJ, Cao Y, Moore JP, Ho DD, and Barbas CF III: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994;266:1024-1027.
15. Barbas CF III, Bjorling E, Chiodi F, Dunlop N, Cababa D, Jones TM, Zebedee SL, Persson MA, Nara PL, Norrby E, and Burton DR: Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci USA 1992;89:9339-9343.
16. Burton DR, Barbas CF III, Persson MA, Koenig S, Chanock RM, and Lerner RA: A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci USA 1991;88:10134-10137.
17. Beretta A and Dalgleish AG: B-cell epitopes. AIDS 1994;8(Suppl. 1):133-145.
18. Thiriart C, Francotte M, Cohen J, Collignon C, Delers A, Kummert S, Molitor C, Gilles D, Roelants P, van Wijnendaele F, de Wilde M, and Bruck C: Several antigenic determinants exposed on the gp120 moiety of HIV gp160 are hidden on the mature gp120. J Immunol 1989;143:1832-1836.
19. Abacioglu YH, Fouts RT, Laman JD, Classen E, Pincus SH, Moore JP, Roby CA, Kamin-Lewis R, and Lewis GK: Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res Hum Retroviruses 1994;10:371-381.
20. McKeating JA, Shotton C, Cordell J, Graham S, Balfe P, Sullivan N, Charles M, Page M, Bolmstedt A, Olofsson S, Kayman SC, Wu Z, Pinter A, Dean C, Sodroski J, and Weiss RA: Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. J Virol 1993; 67:4932-4944.
21. Dowbenko D, Nakamura G, Fennie C, Shimasaki C, Riddle L, Harris R, Gregory T, and Lasky L: Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies. J Virol 1988;62:4703-4711.
22. Lasky LA, Nakamura G, Smith DH, Fennie C, Shimasaki C, Patzer E, Berman P, Gregory T, and Capon DJ: Delineation of a region of the human immunodeficiency virus type gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 1987;50:975-985.
23. Veronese FD, Rahman R, Pal R, Boyer C, Romano J, Kalyanaraman VS, Nair BC, Gallo RC, and Sarngadharan MG: Delineation of immunoreactive, conserved regions in the external glycoprotein of the human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1992;8:1125-1132.
24. Pal R, Veronese FD, Nair BC, Rahman R, Hoke J, Mumbauer SW, and Sarngadharan MG: Characterization of a neutralizing monoclonal antibody to the external glycoprotein of HIV-1. Intervirology 1992;86:86-93.
25. Matsushita S, Robert-Guroff M, Rusche J, Koito A, Hattori T, Hoshino H, Javaherian K, Takatsuki K, and Putney S: Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol 1988;62:2107-2114.
26. Moore JP, Sattentau QJ, Wyatt R, and Sodroski J: Probing the structure of the human immunodeficiency virus glycoprotein gp120 with a panel of monoclonal antibodies. J Virol 1994;68:469-484.
27. Moore JP, Sattentau QJ, Yoshiyama H, Thali M, Charles M, Sullivan N, Poon S-W, Fung MS, Traincard F, Pinkus M, Robey G, Robinson JE, Ho DD, and Sodroski J: Probing the structure of the V2 domain of the human immunodeficiency virus glycoprotein gp120 with a panel of monoclonal antibodies: Human immune response to the V1 and V2 domains. J Virol 1993;67:6136-6151.
28. Moore JP, Thali M, Jameson BA, Vignaux F, Lewis GK, Poon S-W, Charles M, Fung MS, Sun B, Durda PJ, Akerblom L, Wahren B, Ho DD, Sattentau QJ, and Sodroski J: Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: Probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop. J Virol 1993;67:4785-4797.
29. Sattentau QJ and Moore JP: HIV-1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med 1995; 182:185-196.
30. Celada F, Cambiaggi C, Maccari J, Burastero S, Gregory T, Patzer E, Porter J, McDanal C, and Matthews T: Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding. J Exp Med 1990;172:1143-1150.
31. Harlow E and Lan D: Antibodies. A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1988.
32. Gershoni JM: Protein blotting: A manual. Methods Biochem Anal 1988;33:1-58.
33. Nygren A, Bergman T, Matthews T, Jornval H, and Wigzell H: 95- and 25-kDa fragments of the human immunodeficiency virus envelope glycoprotein gp120 bind to the CD4 receptor. Proc Natl Acad Sci USA 1988;85:6543-6546.
34. Mosckovitz R and Gershoni JM: Three possible disulfides in acetylcholine receptor α-subunit. J Biol Chem 1988;263:1017-102.
35. Haas SJ and Smith GP: Rapid sequencing of viral DNA from filamentous bacteriophage. Biotechniques 1993;15:422-431.
36. Smith GP and Scott JK: Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol 1993;217:228-257.
37. Clerici M, Lucey DR, Zajac RA, Boswell RN, Gebel HM, Takahashi H, Berzofsky JA, and Shearer GM: Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. J Immunol 1991;146:2214-2219.
38. Falk K, Rotzchke O, Deres K, Metzger J, Jung G, Stevanovic S, and Rammensee H-G: Identification of naturally processed viral non-apeptides allows their quantification of infected cells and suggests an allele-specific T-cell epitope forecast. J Exp Med 1991;174:425-434.
39. Manca F, Habeshaw J, and Dalgleish A: The naive repertoire of human T helper cells specific for gp120, the envelope glycoprotein of HIV. J Immunol 1991;146:1964-1971.
40. Berzofsky JA: Human immunodeficiency virus: Structural features of T-cell epitopes and their use in vaccine development. In: Viruses and the Cellular Immune Response. (Thomas DB, ed.). National Institute for Medical Research, London, 1993, pp. 101-126.
41. Rusche JR, Javaherian K, McDanal C, Petro J, Lynn DL, Grimaila R, Langlois A, Gallo RC, Arthur LO, Bolognesi DP, Putney SD, Matthews TJ, and Fischinger PJ: Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24 amino-acid sequence of the viral envelope, gp120. Proc Natl Acad Sci USA 1988;85:3198-3202.
42. Palker TJ, Clark ME, Langlois AJ, Matthews TJ, Weinhold KJ, Randall RR, Bolognesi DP, and Haynes BF: Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci USA 1988;85:1932-1936.
43. Goudsmit J, Debouk C, Meloen RH, Smit L, Bakker M, Asher DM, Wolff AV, Gibbs CJ Jr, and Gajdusek DC: Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci USA 1988;85:4478-4482.
44. Bomford R, Stapleton M, Winsor S, McKnight A, and Andronova T: The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants. AIDS Res Hum Retroviruses 1992;8:1765-1771.
45. Akerblom L, Nara P, Dunlop N, and Morein B: Cross-neutralizing antibodies to HIV-1 in mice after immunization with gp160 ISCOMs. Dissection of the immune response. AIDS Res Hum Retroviruses 1991;7:621-627.
46. Gershoni JM, Denisova GF, Raviv D, Smorodinsky NI, and Buyaner D: HIV binding to its receptor creates specific epitopes for CD4/gp120 complex. FASEB J 1993;7:1185-1187.
47. Denisova G, Zwickel J, and Gershoni JM: Conformational transitions in immunoglobulins: Antigen induced epitopes in anti-gp120 V3-loop antibody. FASEB J 1995;9:127-132.
48. Kang C-Y, Hariharan K, Nara PL, Sodroski J, and Moore JP: Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120. J Virol 1994;68:5854-5862.
49. Manca F, Seravalli E, Valle MT, Fenoglio D, Kunkl A, Pira GL, Zolla-Pazner S, and Celada F: Non-covalent complexes of HIV gp120 with CD4 and/or MAbs enhance activation of gp120-specific T clones and provide intermolecular help for anti-CD4 antibody production. Int Immunol 1993;5:1109-1117.
50. Syu W Jr, Huang J-H, Essex M, and Lee T-H: The N-terminal region of the human immunodeficiency virus envelope glycoproteins gp120 contains potential binding sites for CD4. Proc Natl Acad Sci USA 1990;87:3695-3699.
51. Celis E and Chang TW: Antibodies to hepatitis B surface antigen potentiate the response of human T lymphocyte clones to the same antigen. Science 1984;224:297-299.
52. Lanzavecchia A: Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu Rev Immunol 1990;8:773-793.
53. Manca F, Fenoglio D, Pira GL, Kunkl A, and Celada F: Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies. J Exp Med 1991;173:37-48.
54. Bolmstedt A, Olofsson S, Sjogren-Jansson E, Jeansson S, Sjoblom I, Akerblom L, Hansen J-ES, and Hu S-L: Carbohydrate determinant NeuAc-Galβ(1-4) of N-linked glycans modulates the antigenic activity of human immunodeficiency virus type 1 glycoprotein gp120. J Gen Virol 1992;73:3099-3105.